Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03694444
Recruitment Status : Not yet recruiting
First Posted : October 3, 2018
Last Update Posted : January 29, 2019
Sponsor:
Information provided by (Responsible Party):
Amyndas Pharmaceuticals S.A.

Brief Summary:

A Phase 2a Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor Analog, AMY-101, in Adults with gingivitis.

The study is a 3-month randomized, double-blind, split-mouth study of adults with existing chronic periodontal inflammation determined by the level of gingival index and bleeding on probing. The primary endpoint of change in gingival index will be evaluated at 21, 28 and 90 days after initial treatment (baseline treatment). Subjects will also be followed at Day 3, 7, 14, 21, 28 and 90 for safety evaluations. Change in bleeding on probing plaque index, pocket depth, clinical attachment level and GCF levels of pro-inflammatory cytokines and complement factors will be assessed as secondary outcome measures. Composition of subgingival biofilm will be assessed as an exploratory endpoint.

Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. After clinical assessments and sample collection at baseline, both test and placebo treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.


Condition or disease Intervention/treatment Phase
Gingivitis Drug: AMY-101 Other: Water for injection Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a Clinical Trial to Assess the Safety and Efficacy of C3 Inhibitor AMY-101, in Adults With Gingivitis
Estimated Study Start Date : March 2019
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : March 2020

Arm Intervention/treatment
Active Comparator: AMY-101 treatment
Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the AMY-101 treatment arm after clinical assessments and sample collection at baseline, test treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
Drug: AMY-101
C3 complement inhibitor

Placebo Comparator: Placebo
Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the placebo arm, after clinical assessments and sample collection at baseline, placebo treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
Other: Water for injection
Placebo




Primary Outcome Measures :
  1. Change in mean gingival index (MGI) [ Time Frame: Assessed at 28 days after initial treatment ]

Secondary Outcome Measures :
  1. Gingival inflammation [ Time Frame: Assessed at baseline and Days 3, 7, 14, 21, and 28. ]
  2. Ulceration in the oral cavity [ Time Frame: Assessed at baseline and Days 3, 7, 14, 21, and 28. ]
  3. Oral infections [ Time Frame: Assessed at baseline and Days 3, 7, 14, 21, and 28. ]
  4. Changes in mean gingival index [ Time Frame: Assessed at Days 21 and 90 ]
  5. Changes in mean bleeding on probing (BOP) [ Time Frame: Assessed at baseline and 21, 28 and 90 days ]
  6. Changes in mean probing depth (PD) [ Time Frame: Assessed at baseline and 21, 28 and 90 days ]
  7. Number of sites with PD greater or equal to 5 mm [ Time Frame: Assessed at baseline and 21, 28 and 90 days ]
  8. Changes in mean clinical attachment level (CAL) [ Time Frame: Assessed at baseline and 21, 28 and 90 days ]
  9. Changes in plaque index (PI) [ Time Frame: Assessed at baseline and 21, 28 and 90 days ]
  10. Levels of gingival crevicular fluid (GCF) [ Time Frame: Assessed at baseline and 21, 28 and 90 days ]
  11. Levels of proinflammatory mediators in the GCF [ Time Frame: Assessed at baseline and 21, 28 and 90 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of signed and dated informed consent form.
  2. Stated willingness to comply with all study procedures and availability for the duration of the study.
  3. Age 18-65 years old.
  4. Equal to or greater than 18 natural teeth present (excluding third molars).
  5. Generalized periodontal inflammation determined by modified gingival index and percent bleeding on probing (MGI≥2.0, BOP ≥ 40%).
  6. In good general health as evidenced by medical history.
  7. For women of reproductive potential, use of licensed hormonal contraception or barrier methods or abstinence for at least 1 month prior to screening and agreement to use such a method during study participation.
  8. For men of reproductive potential, agreement to use condoms or other methods to ensure effective contraception with partner.

Exclusion Criteria:

  1. Presence of orthodontic appliances (including fixed lingual retainer).
  2. A soft or hard tissue tumor of the oral cavity.
  3. Carious lesions requiring immediate treatment.
  4. Participation in any other clinical study within 30 days of screening or during the study.
  5. Antibiotic therapy within the last 30 days.
  6. Chronic use (≥3 times/week) of anti-inflammatory medications [e.g., non-steroidal anti-inflammatory drugs (NSAIDs), steroids]. Low dose (<325 mg) aspirin is allowed.
  7. Immune compromised subjects (e.g., subjects with HIV infection, neutropenia, complement deficiency, etc.).
  8. Any medical history or any concomitant medication that might affect the assessment of the study treatment or periodontal tissues, such as diabetes (irrespective of level of control), rheumatoid arthritis, Crohn's disease, nifedipine, phenytoin (Dilantin), anticoagulant medications (e.g., warfarin [Coumadin] etc.), ongoing cancer treatment either with radiation or chemotherapy.
  9. Involvement in the planning or conduct of the study.
  10. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or interfere with interpretation of the subject's study results.
  11. Pregnancy or lactation.
  12. Uncontrolled chronic diseases (e.g., kidney disease, COPD, pulmonary fibrosis, Hepatitis C)
  13. Autoimmune disorders (Down's Syndrome, Sjogren's Disease, Psoriasis, Chediak-Higashi Syndrome)
  14. Conditions requiring antibiotic prophylaxis.
  15. Periodontal therapy within the past one year.
  16. Gross tooth decay, as determined by the investigator.
  17. Periodontal or dental abscesses.
  18. Root fragments, pericoronitis, endo-perio lesions.
  19. Use of cigarettes or other tobacco products (including e-cigarette or recreational drug use) within 1 year before the screening visit.

Layout table for additonal information
Responsible Party: Amyndas Pharmaceuticals S.A.
ClinicalTrials.gov Identifier: NCT03694444     History of Changes
Other Study ID Numbers: AMY-101/perio1
First Posted: October 3, 2018    Key Record Dates
Last Update Posted: January 29, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gingivitis
Gingival Diseases
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Complement Inactivating Agents
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents